Mechanism of action

Tesamorelin is an agonist at the growth hormone-releasing hormone receptor (GHRH-R) on somatotroph cells of the anterior pituitary. Receptor binding activates Gs-protein-coupled signaling (cAMP/PKA) and stimulates the synthesis and pulsatile release of endogenous growth hormone (GH), which in turn drives hepatic IGF-1 production. Because the axis remains under negative feedback by somatostatin and IGF-1, the physiological secretion pattern is largely preserved, a distinction from administration of exogenous GH. Structurally, tesamorelin corresponds to human GHRH(1-44) carrying a trans-3-hexenoyl group at the N-terminus; this modification increases resistance to degradation by dipeptidyl peptidase-4 (DPP-4). Half-life figures depend on formulation and study conditions. The 2015 FDA label for original EGRIFTA reports means of 26 minutes in healthy subjects and 38 minutes in HIV-infected patients after 14 consecutive days of subcutaneous administration. Roughly 30 minutes is therefore only a rounded historical reference for that formulation. EGRIFTA WR was studied differently: its 2025 label reports 11 minutes after a single subcutaneous administration in healthy subjects. These references do not establish a universal half-life for tesamorelin research material. Downstream effects on lipolysis and visceral adipose tissue have been examined in clinical trials.

State of evidence

Tesamorelin is one of the few peptides in this class with regulatory approval: in 2010 the US FDA approved it under the brand name Egrifta for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The approval rests on randomized, placebo-controlled multicenter trials (Falutz et al., NEJM 2007; Falutz et al., JAIDS 2010), in which tesamorelin reduced visceral adipose tissue compared with placebo; the effect regressed after discontinuation in the extension phases. Further clinical work has examined, among other endpoints, muscle fat content and muscle area in adults with HIV (Adrian et al., 2019). Important context: the approval covers only this narrowly defined indication. The named EGRIFTA authorization does not cover general metabolic or body-composition claims outside that HIV indication; the cited data for those questions remain limited. Long-term data on hard clinical endpoints are lacking, and effects on the IGF-1 axis are discussed in the literature as requiring monitoring. No conclusions about efficacy or safety outside controlled studies can be drawn from this evidence.

Questions about the research

What is tesamorelin studied for in research?

The focus is the growth hormone axis: as a GHRH analog, tesamorelin stimulates the pulsatile release of endogenous growth hormone. The best-studied clinical context is the reduction of visceral adipose tissue in HIV-associated lipodystrophy, the indication for which the FDA approved the substance as Egrifta. Studies have additionally examined body-composition endpoints such as muscle fat content in adults with HIV.

What is the state of the evidence on tesamorelin?

Randomized, placebo-controlled multicenter trials exist for the approved indication, on the basis of which the FDA granted approval in 2010. The named EGRIFTA authorization covers a narrowly defined HIV-associated indication, not general body-composition claims or research material. Outside that indication, the cited data remain limited. Long-term data on hard clinical endpoints are lacking, so no conclusions about efficacy or safety outside controlled studies can be drawn.

Sources

1. Falutz et al., NEJM 2007DOI: 10.1056/NEJMoa072375PMID: 18057338
2. Falutz et al., JAIDS 2010DOI: 10.1097/QAI.0b013e3181cbdaffPMID: 20101189
3. Adrian et al., J Frailty Aging 2019DOI: 10.14283/jfa.2018.45PMID: 31237318
4. Drugs@FDA: Egrifta (Tesamorelin), NDA 022505
5. FDA: Original EGRIFTA Prescribing Information, 2015, section 12.3
6. FDA: EGRIFTA WR Prescribing Information, 2025, section 12.3
7. FDA: EGRIFTA SV Prescribing Information, 2024, section 12.3

Mechanism of action

Tesamorelin is an agonist at the growth hormone-releasing hormone receptor (GHRH-R) on somatotroph cells of the anterior pituitary. Receptor binding activates Gs-protein-coupled signaling (cAMP/PKA) and stimulates the synthesis and pulsatile release of endogenous growth hormone (GH), which in turn drives hepatic IGF-1 production. Because the axis remains under negative feedback by somatostatin and IGF-1, the physiological secretion pattern is largely preserved, a distinction from administration of exogenous GH. Structurally, tesamorelin corresponds to human GHRH(1-44) carrying a trans-3-hexenoyl group at the N-terminus; this modification increases resistance to degradation by dipeptidyl peptidase-4 (DPP-4). Half-life figures depend on formulation and study conditions. The 2015 FDA label for original EGRIFTA reports means of 26 minutes in healthy subjects and 38 minutes in HIV-infected patients after 14 consecutive days of subcutaneous administration. Roughly 30 minutes is therefore only a rounded historical reference for that formulation. EGRIFTA WR was studied differently: its 2025 label reports 11 minutes after a single subcutaneous administration in healthy subjects. These references do not establish a universal half-life for tesamorelin research material. Downstream effects on lipolysis and visceral adipose tissue have been examined in clinical trials.

State of evidence

Tesamorelin is one of the few peptides in this class with regulatory approval: in 2010 the US FDA approved it under the brand name Egrifta for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. The approval rests on randomized, placebo-controlled multicenter trials (Falutz et al., NEJM 2007; Falutz et al., JAIDS 2010), in which tesamorelin reduced visceral adipose tissue compared with placebo; the effect regressed after discontinuation in the extension phases. Further clinical work has examined, among other endpoints, muscle fat content and muscle area in adults with HIV (Adrian et al., 2019). Important context: the approval covers only this narrowly defined indication. The named EGRIFTA authorization does not cover general metabolic or body-composition claims outside that HIV indication; the cited data for those questions remain limited. Long-term data on hard clinical endpoints are lacking, and effects on the IGF-1 axis are discussed in the literature as requiring monitoring. No conclusions about efficacy or safety outside controlled studies can be drawn from this evidence.

Questions about the research

What is tesamorelin studied for in research?

The focus is the growth hormone axis: as a GHRH analog, tesamorelin stimulates the pulsatile release of endogenous growth hormone. The best-studied clinical context is the reduction of visceral adipose tissue in HIV-associated lipodystrophy, the indication for which the FDA approved the substance as Egrifta. Studies have additionally examined body-composition endpoints such as muscle fat content in adults with HIV.

What is the state of the evidence on tesamorelin?

Randomized, placebo-controlled multicenter trials exist for the approved indication, on the basis of which the FDA granted approval in 2010. The named EGRIFTA authorization covers a narrowly defined HIV-associated indication, not general body-composition claims or research material. Outside that indication, the cited data remain limited. Long-term data on hard clinical endpoints are lacking, so no conclusions about efficacy or safety outside controlled studies can be drawn.

Sources

1. Falutz et al., NEJM 2007DOI: 10.1056/NEJMoa072375PMID: 18057338
2. Falutz et al., JAIDS 2010DOI: 10.1097/QAI.0b013e3181cbdaffPMID: 20101189
3. Adrian et al., J Frailty Aging 2019DOI: 10.14283/jfa.2018.45PMID: 31237318
4. Drugs@FDA: Egrifta (Tesamorelin), NDA 022505
5. FDA: Original EGRIFTA Prescribing Information, 2015, section 12.3
6. FDA: EGRIFTA WR Prescribing Information, 2025, section 12.3
7. FDA: EGRIFTA SV Prescribing Information, 2024, section 12.3